| 42.7083 -0.627 (-1.45%) | 05-22 15:24 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 52.82 | 1-year : | 56.27 |
| Resists | First : | 45.23 | Second : | 48.18 |
| Pivot price | 43.65 |
|||
| Supports | First : | 40.45 | Second : | 33.66 |
| MAs | MA(5) : | 41.9  |
MA(20) : | 43.75 |
| MA(100) : | 42.15 |
MA(250) : | 32.7 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 38.5 |
D(3) : | 25.3 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 48.18 | Low : | 17.37 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BBC ] has closed above bottom band by 34.6%. Bollinger Bands are 25.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 43.57 - 43.82 | 43.82 - 44.04 |
| Low: | 42.13 - 42.41 | 42.41 - 42.65 |
| Close: | 42.32 - 42.75 | 42.75 - 43.15 |
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies.Effective February 27, this Fund's name changed from Virtus LifeSci Biotech Clinical Trials ETF to Virtus Biotech Clinical Trials ETF.
Fri, 22 May 2026
(BBC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Thu, 14 May 2026
Inhibrx Inc stock (US45720L1070): Biotech firm in Virtus ETF holdings - AD HOC NEWS
Mon, 11 May 2026
(BBC) Risk Channels and Responsive Allocation - Stock Traders Daily
Sun, 19 Apr 2026
Liquidity Mapping Around (BBC) Price Events - Stock Traders Daily
Thu, 08 Jan 2026
What's Going On With Alumis Stock Thursday? - Benzinga
Mon, 01 Dec 2025
Biotech ETF (BBC) Hits New 52-Week High - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|